Evidence mapPaperPMID 36032038Full record

ArticleEuropean heart journal. Case reports2022

Acute-phase administration of ivabradine supported by intra-aortic balloon pump induces myocardial recovery without significant haemodynamic worsening in a patient with acute fulminant myocarditis: a case report.

Moriyasu Ando, Naoki Watanabe, Keita Saku, Itsuro Morishima

Abstract readCase Reports
In one paragraph

Article in European heart journal. Case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Moriyasu AndoDepartment of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
Naoki WatanabeDepartment of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
Keita SakuDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, Japan.
Itsuro MorishimaDepartment of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.ORCID https://orcid.org/0000-0002-1444-090X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ivabradine can reduce the heart rate without affecting myocardial contractility or vascular tone. Current guidelines recommend its use for treating patients with chronic heart failure who have a high heart rate (≥75 b.p.m.) and persistent symptoms despite guideline-directed therapy. Nonetheless, little is known about its efficacy in patients with acute cardiogenic shock. We report a case of successful treatment of cardiogenic shock. Case summary: A 53-year-old previously healthy man was admitted due to cardiogenic shock with acute fulminant myocarditis. The patient was placed on intra-aortic balloon pump support and was given guideline-directed therapy including inotropic agents and furosemide. However, no improvement was seen in haemodynamics and the patient was in sinus tachycardia (116 b.p.m.). On Day 2, ivabradine therapy was initiated to reduce the myocardial workload and stabilize the haemodynamic parameters. As heart rate decreased, his symptoms improved and urine output increased without affecting the blood pressure. Subsequently, the patient recovered from cardiogenic shock. The intra-aortic balloon pumping was discontinued on Day 7, and the patient was discharged on Day 22. Discussion: Ivabradine has the potential to induce rapid cardiac recovery and haemodynamic improvement in the acute phase of heart failure if supported by intra-aortic balloon pump.

Indexed as

Cardiogenic shockCase reportFulminant myocarditisIntra-aortic balloon pumpIvabradine

Identifiers

PMID36032038
PMCPMC9411543

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.